Navigation Links
OrbusNeich Files Patent Infringement Actions Against Boston Scientific in Germany and the Netherlands
Date:2/20/2013

FORT LAUDERDALE, Fla., Feb. 20, 2013 /PRNewswire/ -- OrbusNeich today announced that OrbusNeich Medical GmbH and Orbus International B.V., subsidiaries of OrbusNeich Medical, Inc., (collectively, "OrbusNeich") have commenced patent infringement actions in Germany and The Netherlands against Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific") and its distribution affiliates in those countries.

The Complaints allege that Boston Scientific infringed two European patents covering certain novel stent designs.  The two patents, held by OrbusNeich, are designated EP 2 311 412 and EP 1 341 482.  OrbusNeich alleges that these patents are infringed by several of Boston Scientific's coronary stent systems, including the "PROMUS Element™", "PROMUS Element™ Plus", "OMEGA™ PtCr", and "TAXUS™ Element™" lines of stents.

OrbusNeich is seeking, among other things, a preliminary injunction prohibiting Boston Scientific from marketing and selling the infringing stents in Germany and The Netherlands.  OrbusNeich also seeks damages for all sales of infringing products and a recall of commercially distributed, but not yet used stents in the Netherlands and to seize commercially distributed, but not yet used stents that are still in the possession of Boston Scientific in Germany.

"We will take all necessary actions to protect OrbusNeich from unlawful competitive practices," said Al Novak , Chairman and Chief Executive Officer of OrbusNeich.  "Through these proceedings, we are seeking to safeguard these technologies for the benefit of our physician customers and their patients as well as our investors and employees."

On February 11, 2013, OrbusNeich received a favorable ruling from the European Patent Office (EPO) in connection with EP 1 341 482, one of the two patents asserted against Boston Scientific in these lawsuits. The EPO upheld the validity of claim 1 of the '482 patent, as amended, over an opposition filed by Boston Scientific  and Terumo Kabushiki Kaisha.  The EPO found that claim 1 of the '482 patent met all requirements of the European Patent Convention, and that the stents covered by the claim were novel and inventive over the prior art.

A patent infringement action was also filed by OrbusNeich in the United States in 2009. That suit has currently been stayed pending review of the patents under re-examination procedures in the United States Patent and Trademark Office.  The Company notes that it is also reviewing its options with respect to this litigation. 

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

Global Media Contacts:

Dan Katcher / Jamie Moser
Joele Frank , Wilkinson Brimmer Katcher
(212) 355-4449

 


'/>"/>
SOURCE OrbusNeich
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
2. OrbusNeich Announces Favorable Ruling From the European Patent Office
3. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
4. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
5. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
6. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
7. Sunpeaks Ventures Files Defamation Lawsuit
8. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
9. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
10. DataMotion Files Provisional Patent for Technology that Enables Easy and Secure Doctor-Patient Email Interaction
11. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Site Profile: --> ... The Speech Recognition People, announced their latest primary healthcare case study ... reduce turnaround times and to save the practice money. ... 2013 Challenge: --> ,- Wirral CCG ,- ... Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
(Date:2/4/2016)...  The Senior Care Pharmacy Coalition (SCPC) today ... Jason Chaffetz (R-UT) and Ranking Member ... , "Developments in the Prescription Drug Market," to ... about abusive pharmacy benefit manager (PBM) pricing practices. ... Member Elijah Cummings (D-MD) are diligent, serious lawmakers ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is ... in the field of Pharmaceuticals. Montoya is the Regulatory ... Manufacturing and ... Becton Dickinson provides healthcare institutions, clinical laboratories ... throughout fifty countries across the globe. ...
Breaking Medicine Technology:
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... The ... held annually in this country. The AutismOne 2016 Conference, which is being held May ... they often won’t hear elsewhere about helpful interventions and causes of chronic illness in ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe A. ... a joint enrollment and degree completion agreement. The agreement, which begins with ... at FHU|Dickson. , The agreement allows students to be jointly admitted to ...
Breaking Medicine News(10 mins):